Izumi T, Inoue T, Kitagawa N, Nishi N, Shimanaka S, Takahashi Y, Kusumi I, Odagaki Y, Denda K, Ohmori T, Koyama T
Department of Psychiatry, Hokkaido University School of Medicine, North 15, West 7, Kita-ku, 060-8638, Sapporo, Japan.
J Affect Disord. 2000 Dec;61(1-2):127-32. doi: 10.1016/s0165-0327(99)00199-8.
Recently, a dopamine hypothesis of depression was put forward, and several studies have demonstrated that direct and indirect dopamine agonists have antidepressant effects.
Using Clinical Global Impressions, we evaluated the efficacy of 4-week treatment of pergolide as an antidepressant adjuvant involving 20 unipolar depressed patients who were refractory to standard treatment with antidepressants.
One patients (5%) were very much improved, seven (35%) much improved, four (20%) minimally improved, six (30%) no change or worse, and two (10%) not assessed. There was no significant difference in any clinical factors between the pergolide responder and non-responder group.
This study was a non-blind open trial, and pergolide was added to tricyclic and heterocyclic antidepressants.
Pergolide may be useful as an antidepressant adjuvant, suggesting a potential role for dopamine-2 stimulation in the antidepressant response.
最近，提出了抑郁症的多巴胺假说，并且多项研究已证明直接和间接多巴胺激动剂具有抗抑郁作用。
使用临床总体印象量表，我们评估了培高利特作为抗抑郁辅助药物对20名对标准抗抑郁药治疗无效的单相抑郁症患者进行4周治疗的疗效。
1名患者（5%）显著改善，7名（35%）明显改善，4名（20%）稍有改善，6名（30%）无变化或病情恶化，2名（10%）未评估。培高利特反应者和无反应者组之间在任何临床因素上均无显著差异。
本研究为非盲开放试验，且培高利特被添加到三环和杂环抗抑郁药中。
培高利特可能作为抗抑郁辅助药物有用，提示多巴胺-2刺激在抗抑郁反应中具有潜在作用。
